DGAP-News

amp biosimilars AG appoints Professor Dr. Dr. Rolf G. Werner as chairman of the Scientific Board

DGAP-News: amp biosimilars AG / Key word(s): Change of Personnel
amp biosimilars AG appoints Professor Dr. Dr. Rolf G. Werner as
chairman of the Scientific Board

28.04.2015 / 07:30

---------------------------------------------------------------------

amp biosimilars AG appoints Professor Dr. Dr. Rolf G. Werner as chairman of
the Scientific Board

- Former head of global biopharmaceuticals at Boehringer Ingelheim

- Honorary Senator and professor at the University of Tübingen

- Experience in the development of numerous biosimilars and
biopharmaceuticals

Hamburg, 28. April 2015 - amp biosimilars AG (ISIN: DE00A0SMU87), a company
specializing in the development of high quality biosimilars, has named
Professor Dr. Dr. Rolf G. Werner to head up the Scientific Board, effective
immediately. In his new role, Professor Werner will serve as the "Chairman
of the Scientific Board".

Rolf G. Werner is a Professor of Industrial Biotechnology and an Honorary
Senator at the Eberhard Karls University Tübingen. He is one of the world's
leading experts in research, development and production of pharmaceutical
biotechnologies, with more than 35 years of industry experience in various
leadership positions at Boehringer Ingelheim, including head of global
biopharmaceuticals. The company's more than 47,000 employees and revenues
of EUR 13.3 billion in 2014 make Boehringer Ingelheim the largest research
pharmaceutical company in Germany.

Prof. Werner's scientific contributions include more than 180 publications,
20 patents and 15 scientific films. His work has been honored with the City
of Vienna Prize for his outstanding contributions to science and by the
administrative district of Hangzhou, China, where he was named a Hangzhou
Qian Jiang Distinguished Expert.

"We are thrilled to have Professor Werner on our team," says Dr. Marc W.
Hentz, Chief Executive Officer of amp biosimilars AG. "His vast expertise
with every aspect of the development and production of biotechnological
materials and pharmaceuticals as well as his international network make him
the ideal partner to help identify and commercialize biosimilar
blockbusters."

"It is nothing less than a moral obligation to help find affordable,
efficient and safe high quality biosimilars that will give the general